Agency Forms Undergoing Paperwork Reduction Act Review, 73311-73313 [2022-25992]
Download as PDF
Federal Register / Vol. 87, No. 228 / Tuesday, November 29, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0137]
Proposed Update to the CDC
Framework for Program Evaluation in
Public Health
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Request for information.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the opening
of a docket to obtain comments and
suggestions to update the CDC
Framework for Program Evaluation in
Public Health (CDC Evaluation
Framework) and associated resources
(e.g., checklists, self-study guide).
Updates to the CDC Evaluation
Framework are needed to continue its
valuable use and service to the
evaluation field and public health.
DATES: Written comments must be
received on or before January 30, 2023.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2022–
0137 by either of the methods listed
below. Do not submit comments by
email. CDC does not accept comments
by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, Program Performance
and Evaluation Office, 1600 Clifton
Road NE, Mailstop H21–10, Atlanta, GA
30329–4027
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Daniel Kidder, CDC Chief Evaluation
Officer, Centers for Disease Control and
Prevention, Program Performance and
Evaluation Office, 1600 Clifton Road
NE, Mailstop H21–10, Atlanta, GA
30329–4027; Telephone: 404.639.6270;
Email: CDCeval@cdc.gov.
SUPPLEMENTARY INFORMATION: The
flexibility and simplicity of the CDC
Evaluation Framework have led to its
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:29 Nov 28, 2022
Jkt 259001
73311
inhibit the conduct of evaluations that
are culturally responsive and address
health equity? What opportunities for
improvement exist?
wide adoption and use beyond CDC and
public health. The CDC Evaluation
Framework has guided CDC and other
evaluators over two decades, as
evidenced by more than 300 citations in
peer-reviewed articles and use in
projects reaching more than 50
countries on six continents. However,
evaluation has evolved since
publication of the framework in 1999; 1
therefore, CDC seeks to update the
framework to align with changes in
evaluation, public health, and federal
policies and practices.
The comments from this Request for
Information, along with input gathered
through other mechanisms (e.g.,
townhall with CDC, interviews with key
federal evaluators, surveys with federal
evaluation staff and leaders), will help
identify how the framework may have
been adapted and used in different
settings, what aspects of the framework
have been useful, any challenges in
using the framework across different
contexts, and gaps that may need to be
addressed. CDC is gathering input from
a variety of audiences, such as federal
evaluators, CDC staff, and CDC funded
partners. Feedback from these sources
will be considered in determining
priority areas to update and revise in the
CDC Evaluation Framework to continue
its valuable use and service to the
evaluation field and public health. The
relevant feedback along with tools,
evidence, and resources in the field and
literature will also be considered in
determining whether to update, revise,
or create new content for the CDC
Evaluation Framework and supporting
resources (e.g., checklists, tools).
Angela K. Oliver,
Request for Information
Executive Secretary, Centers for Disease
Control and Prevention.
Interested persons or organizations
are invited to submit written views,
information, and recommendations.
CDC invites comments specifically on
the following questions, along with
suggestions for improving the CDC
Evaluation Framework:
1. How has the current CDC
Evaluation Framework assisted or not
assisted the public health community in
planning and conducting high-quality
program evaluations? What specifically
helped or did not help?
2. Which contexts has the current
CDC Evaluation Framework worked
well for and for which contexts has it
not worked well? What specifically did
or did not work and why?
3. How does the current CDC
Evaluation Framework promote or
1 Centers for Disease Control and Prevention.
Framework for program evaluation in public health.
MMWR 1999;48(No. RR–11).
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Please be clear and specific in the
comments so that CDC can consider the
feedback provided in determining
whether to change or keep specific
aspects of the CDC Evaluation
Framework. The CDC Evaluation
Framework and associated resources
can be found here in the Supporting
Materials tab of the docket and at
https://www.cdc.gov/evaluation/
framework/index.htm.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign.
Dated: November 23, 2022.
[FR Doc. 2022–25997 Filed 11–28–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–23–22BC]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Enhancing
Data-driven Disease Detection in
Newborns (ED3N)’’ to the Office of
Management and Budget (OMB) for
E:\FR\FM\29NON1.SGM
29NON1
khammond on DSKJM1Z7X2PROD with NOTICES
73312
Federal Register / Vol. 87, No. 228 / Tuesday, November 29, 2022 / Notices
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on December
6, 2021 to obtain comments from the
public and affected agencies. CDC
received one comment related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
VerDate Sep<11>2014
16:29 Nov 28, 2022
Jkt 259001
Proposed Project
Enhancing Data-driven Disease
Detection in Newborns (ED3N)—New—
National Center for Environmental
Health (NCEH), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Newborn Screening and
Molecular Biology Branch (NSMBB), in
the National Center for Environmental
Health (NCEH) Division of Laboratory
Science (DLS), has the only laboratory
in the world devoted to ensuring the
accuracy of newborn screening (NBS)
tests in every state and more than 78
countries. NSMBB supports NBS
programs by conducting research,
developing methods, and performing
analyses by using complex, state-of-theart molecular and biochemical
techniques for identifying risk factors
for diseases of public health importance.
Both NSMBB and state NBS programs
are experiencing increased data analytic
challenges associated with continued
expansion of the number of newborn
screening diseases, increased
complexity of disease detection, and
difficulties in correlating disease
markers with disease risk. Further, the
addition of late-onset diseases to NBS
panels necessitates a better way to
routinely capture clinical information
and outcomes so that NBS programs can
fully appreciate the spectrum of disease
they are detecting.
The NSMBB is requesting a three-year
Paperwork Reduction Act (PRA)
clearance for Enhancing Data-driven
Disease Detection in Newborns (ED3N),
a new national NBS data platform, that
will address these analytic and postanalytic challenges and promote sharing
of molecular, biochemical, and clinical
information amongst NBS partners. The
information will better equip NSMBB
and newborn screening partners to
assess disease risk and will help
harmonize approaches for disease
detection in newborns. Given the rarity
of newborn screening diseases, it is
imperative that data be collected and
analyzed at a national level in order to
glean useful insights and to analyze
trends. The NSMBB is best suited to
oversee this work given its role in
providing technical assistance to NBS
programs nationally. Numerous studies
along with presentations by NBS
programs suggest that gaps in
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
programmatic resources and expertise
are hampering the ability to perform
more complex data analytics resulting
in low positive predictive values for a
number of conditions (which
subsequently results in higher false
positive and negative rates and
downstream burden to families and the
medical system). Smaller-scale work on
the use of post-analytical tools such as
machine learning algorithms have
shown that incorporation of these
elements into newborn screening can
improve detection rates, while reducing
false positives. These studies, however,
have been limited to single sites and
have not been integrated into the daily
workflow of high-throughput NBS
programs. Without this project, NBS
programs will continue to be unable to
keep up with the increasing complexity
and future demands of screening,
perpetuating inequities in screening
across the nation.
There are 53 domestic NBS programs
in the United States. A ‘‘respondent’’
refers to a single NBS program. Given
that data submission will ultimately be
accomplished through automatic
electronic data transfer, each
respondent’s burden hours were split
into two estimates: (1) the one-time
need to set-up, test, and implement the
electronic data transfer mechanism; and
(2) the ongoing automatic electronic
data transfer occurring after initial setup. Initial set-up time burden was
estimated based on analysis of similar
data transfer projects embarked upon by
NBS programs as well as brief
discussions with NBS Program
Laboratory Information Management
System vendors. The one-time burden to
set-up the data transfer interface was
estimated to be 40 hours total. For
purposes of annualizing this component
of burden over the three-year period of
this request, the 53 respondents are
represented as 18 respondents in the
table below (53/3 = 17.67, rounded to
18). Ongoing daily data submission
burden was estimated assuming
automatic transfer thereafter, 365 days
per year. The estimated burden per
response is one minute.
CDC requests OMB approval for an
estimated 1,042 annualized burden
hours. There are no costs to respondents
other than their time to participate.
E:\FR\FM\29NON1.SGM
29NON1
73313
Federal Register / Vol. 87, No. 228 / Tuesday, November 29, 2022 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Newborn Screening Programs ........................
Set-up of ED3N Data Elements .....................
Ongoing transfer of ED3N Data Elements ....
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
Food and Drug Administration
Microbiota for Transplantation to Treat
Clostridium difficile Infection Not
Responsive to Standard Therapies’’
dated July 2013.
DATES: The announcement of the
guidance is published in the Federal
Register on November 29, 2022.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
[Docket No. FDA–2013–D–0811]
Electronic Submissions
Enforcement Policy Regarding
Investigational New Drug
Requirements for Use of Fecal
Microbiota for Transplantation To Treat
Clostridioides difficile Infection Not
Responsive to Standard Therapies;
Guidance for Industry; Availability
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
[FR Doc. 2022–25992 Filed 11–28–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing the availability of a final
guidance entitled ‘‘Enforcement Policy
Regarding Investigational New Drug
Requirements for Use of Fecal
Microbiota for Transplantation to Treat
Clostridioides difficile Infection Not
Responsive to Standard Therapies;
Guidance for Industry.’’ The guidance
document informs members of the
medical and scientific community and
other interested persons notice that, at
this time, we intend to exercise
enforcement discretion with respect to
the investigational new drug application
(IND) requirements for the use of fecal
microbiota for transplantation (FMT) to
treat Clostridioides difficile (C. difficile)
infection not responding to standard
therapies under limited circumstances
described in the guidance. The guidance
announced in this notice finalizes the
draft guidance entitled ‘‘Enforcement
Policy Regarding Investigational New
Drug Requirements for Use of Fecal
Microbiota for Transplantation to Treat
Clostridium difficile Infection Not
Responsive to Standard Therapies’’
dated March 2016, and supersedes the
guidance entitled ‘‘Enforcement Policy
Regarding Investigational New Drug
Requirements for Use of Fecal
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
Type of respondent
VerDate Sep<11>2014
16:29 Nov 28, 2022
Jkt 259001
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
18
53
1
365
Average
burden per
response
(in hr)
40
1/60
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–D–0811 for ‘‘Enforcement Policy
Regarding Investigational New Drug
Requirements for Use of Fecal
Microbiota for Transplantation to Treat
Clostridium difficile Infection Not
Responsive to Standard Therapies; Final
Guidance for Industry.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
E:\FR\FM\29NON1.SGM
29NON1
Agencies
[Federal Register Volume 87, Number 228 (Tuesday, November 29, 2022)]
[Notices]
[Pages 73311-73313]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30-Day-23-22BC]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Enhancing Data-driven Disease Detection in
Newborns (ED3N)'' to the Office of Management and Budget (OMB) for
[[Page 73312]]
review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
December 6, 2021 to obtain comments from the public and affected
agencies. CDC received one comment related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Enhancing Data-driven Disease Detection in Newborns (ED3N)--New--
National Center for Environmental Health (NCEH), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Newborn Screening and Molecular Biology Branch (NSMBB), in the
National Center for Environmental Health (NCEH) Division of Laboratory
Science (DLS), has the only laboratory in the world devoted to ensuring
the accuracy of newborn screening (NBS) tests in every state and more
than 78 countries. NSMBB supports NBS programs by conducting research,
developing methods, and performing analyses by using complex, state-of-
the-art molecular and biochemical techniques for identifying risk
factors for diseases of public health importance.
Both NSMBB and state NBS programs are experiencing increased data
analytic challenges associated with continued expansion of the number
of newborn screening diseases, increased complexity of disease
detection, and difficulties in correlating disease markers with disease
risk. Further, the addition of late-onset diseases to NBS panels
necessitates a better way to routinely capture clinical information and
outcomes so that NBS programs can fully appreciate the spectrum of
disease they are detecting.
The NSMBB is requesting a three-year Paperwork Reduction Act (PRA)
clearance for Enhancing Data-driven Disease Detection in Newborns
(ED3N), a new national NBS data platform, that will address these
analytic and post-analytic challenges and promote sharing of molecular,
biochemical, and clinical information amongst NBS partners. The
information will better equip NSMBB and newborn screening partners to
assess disease risk and will help harmonize approaches for disease
detection in newborns. Given the rarity of newborn screening diseases,
it is imperative that data be collected and analyzed at a national
level in order to glean useful insights and to analyze trends. The
NSMBB is best suited to oversee this work given its role in providing
technical assistance to NBS programs nationally. Numerous studies along
with presentations by NBS programs suggest that gaps in programmatic
resources and expertise are hampering the ability to perform more
complex data analytics resulting in low positive predictive values for
a number of conditions (which subsequently results in higher false
positive and negative rates and downstream burden to families and the
medical system). Smaller-scale work on the use of post-analytical tools
such as machine learning algorithms have shown that incorporation of
these elements into newborn screening can improve detection rates,
while reducing false positives. These studies, however, have been
limited to single sites and have not been integrated into the daily
workflow of high-throughput NBS programs. Without this project, NBS
programs will continue to be unable to keep up with the increasing
complexity and future demands of screening, perpetuating inequities in
screening across the nation.
There are 53 domestic NBS programs in the United States. A
``respondent'' refers to a single NBS program. Given that data
submission will ultimately be accomplished through automatic electronic
data transfer, each respondent's burden hours were split into two
estimates: (1) the one-time need to set-up, test, and implement the
electronic data transfer mechanism; and (2) the ongoing automatic
electronic data transfer occurring after initial set-up. Initial set-up
time burden was estimated based on analysis of similar data transfer
projects embarked upon by NBS programs as well as brief discussions
with NBS Program Laboratory Information Management System vendors. The
one-time burden to set-up the data transfer interface was estimated to
be 40 hours total. For purposes of annualizing this component of burden
over the three-year period of this request, the 53 respondents are
represented as 18 respondents in the table below (53/3 = 17.67, rounded
to 18). Ongoing daily data submission burden was estimated assuming
automatic transfer thereafter, 365 days per year. The estimated burden
per response is one minute.
CDC requests OMB approval for an estimated 1,042 annualized burden
hours. There are no costs to respondents other than their time to
participate.
[[Page 73313]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hr)
----------------------------------------------------------------------------------------------------------------
Newborn Screening Programs............ Set-up of ED3N Data 18 1 40
Elements.
Ongoing transfer of ED3N 53 365 1/60
Data Elements.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-25992 Filed 11-28-22; 8:45 am]
BILLING CODE 4163-18-P